PMS38 Cost-Effectiveness of Certolizumab Pegol in the Treatment of Active Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis In Romania  by Codreanu, C. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A379
Objectives: To evaluate the cost-effectiveness of certolizumab pegol (CZP) versus 
other subcutaneous (SC) anti-tumour necrosis factors (anti-TNFs) currently licensed 
and reimbursed in Romania (etanercept [ETA] and adalimumab [ADA]) in the treat-
ment of adult patients with active rheumatoid arthritis (RA), axial spondyloarthri-
tis (axSpA; comprising ankylosing spondylitis [AS] and non-radiographic axSpA 
[nr-axSpA]) and psoriatic arthritis (PsA). MethOds: Cost-utility models (Markov 
structure) were developed for each condition, following the EULAR, ASAS and NICE 
guidelines. Clinical efficacy data, disease history and resource use data came from 
published literature. Utilities were derived from EQ-5D data assessed in CZP piv-
otal clinical trials. Published 2013 unit costs were taken from local sources/expert 
opinion. A willingness-to-pay threshold of 3xGDP/capita (87600RON) was consid-
ered. Base-case analysis was conducted from the payer perspective, with lifetime 
horizon, costs and outcomes discounting rates of 3.5%. Sensitivity analyses were 
conducted to test the robustness of the results. Results: In AS, CZP dominates 
ADA and ETA (quality-adjusted life years [QALYs] gain of 0,098 and 0,021; total costs 
lower by 48499.73RON and 8350.28RON, vs ADA and ETA respectively). In nr-axSpA, 
CZP dominates ADA (QALYs gain of 0,257; total costs lower by 13955.14RON). In RA, 
CZP dominates ADA (QALY gain of 0,226; total costs lower by 108694RON) and is 
marginally as effective, but slightly more costly vs ETA (QALYs gain of 0,056, total 
costs higher by 6356RON). In PsA, CZP dominates ADA (QALY gain of 0.05; total 
costs lower by 9397RON) and is less costly, but marginally less effective versus ETA 
(QALYs difference of -0.08, total costs lower by 21484RON). Probabilistic sensitivity 
analysis indicated that CZP has a similar or higher probability of being cost-effective 
when compared to comparators. cOnclusiOns: CZP is a cost-effective treatment 
compared to currently available SC anti-TNFs for the treatment of RA, axSpA and 
PsA in Romania.
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Objectives: Osteoporosis is a condition consisting in reduced bone mass and 
density, thus resulting in an increased risk of fragility fractures. Considering the 
aforementioned, and in conjunction with the complications that osteoporosis 
engenders, a considerable economic burden is imposed on industrialized coun-
tries. The purpose of this study was to determine the thresholds at which treat-
ment initiation becomes cost-effective in Greece, using the fracture risk assessment 
algorithm (FRAX®) developed by WHO and recently adjusted for Greece. MethOds: 
A previously developed state transition Markov model was populated employing 
epidemiological and economic data from Greece. The analysis calculated the cost-
effective intervention thresholds using the Greek FRAX® model, which estimates 
the 10-year probability of a major osteoporotic fracture in subjects with a fracture 
risk equivalent to that of a woman with a prior fragility fracture and no other risk 
fracture. The analysis was undertaken from a third-party payer perspective, assum-
ing a willingness to pay of 30,000€ per QALY gained. Results: In Greece, the drug 
intervention aiming at reducing the fracture risk, was found to be cost-effective 
with a 10-year probability for a major osteoporotic fracture at/or above 12.3% (range: 
7.8%-20.4%) for women and 18.2% (range: 9.6%-34.2%) for men aged from 50 to 59 
years old. When considering women and men aged between 60 and 74 years, the 
threshold was estimated ≥ 8.9% (range: 8.5%-9.2%) and ≥ 9.4% respectively (range: 
8.9%-10.0%), whereas for women and men over 75 years old, the cost-effective 
thresholds were calculated to be ≥ 15.0% (range: 13.0% to 16.0%) and ≥ 11.0% (range: 
10.6%-11.2%) accordingly. Significant age-variations were generally not noticed, 
some exceptions apart, especially for the age-range of 50-55. cOnclusiOns: As 
expected, the cost-effective thresholds obtained via FRAX® were age-dependent in 
both sexes. Therefore, considering these thresholds should lead to cost-effective 
access to therapy of patients with high fracture probability, and ipso facto signifi-
cantly reduce the economic burden of osteoporotic fractures in Greece.
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Objectives: Treat Osteoarthritis (OA) with traditional non-steroidal anti-inflamma-
tory drugs (t-NSAIDs) may be associated with significant gastrointestinal (GI) and 
cardiovascular (CV) events. The objective was to assess the cost-effectiveness (CE) 
of Celecoxib and non selective non steroidal anti-inflammatory drugs therapy for 
the treatment of OA in clinical practice in Spain. MethOds: The CE was assessed 
in patients aged 55+ years with OA and was based on a retrospective decision-tree 
model using distribution, dose and duration of therapies and incidence of GI and 
CV events observed in the pragmatic PROBE-designed 6-month “GI Reasons” trial. 
Effectiveness was expressed in terms of event averted and quality-adjusted life-
years (QALYs) gained. Utility loss in case of adverse events both in values and time 
duration were derived from the published literature. Perspective of the analysis 
was that of the National Health System (NHS) in Spain; cost calculations included 
actual prices of drugs plus cost of adverse events occurred during trial only. The 
analysis was expressed as an incremental CE ratio (ICER) per QALY gained and per 
event averted. Probabilistic and univariate sensitivity analyses, including celecoxib-
price-threshold analysis, were carried out. Results: Data from 7,939 patients were 
included in the analysis. Compared with traditional NSAIDs, celecoxib treatment 
had higher drug costs than traditional NSAIDs (€ 119 vs. € 34), and the overall treat-
ment cost was estimated at € 201 and € 157, respectively. Moreover, celecoxib was 
associated with slightly increase in QALY gain and significant lower incidence of 
gastrointestinal events (p< 0.001) with mean ICERs of € 13,286 per QALY gained and 
after initiating treatment that triggered treatment switching to subsequent thera-
pies upon failure. Scenario 1 compared a treatment sequence of a high efficacy 
biologic therapy followed by conventional DMARD therapy versus a less efficacious 
biologic therapy followed by a cDMARD. Scenario 2 compared two multiple biologic 
treatment sequences with a difference in efficacy between the first biologic in each 
sequence. A sensitivity analysis and a CE efficiency frontier analysis examined the 
effect of varying the difference in DAS-28 < 2.6 rates (Δ Rem) between first-line 
therapies. Results: In scenario 1, a Δ Rem of 10% between the bDMARDs yielded 
a mean per-patient gain of 0.117 QALYs and a mean per-patient increase in total 
cost £2,590, giving an incremental cost-effectiveness ratio (ICER) of £22,112 per 
QALY. In scenario 2, the higher efficacy bDMARD strategy had an ICER of £6,720 
when Δ Rem = 10%. cOnclusiOns: Over a lifetime, treating to the target of DAS-
28< 2.6 with more efficacious therapies in RA patients was cost-effective at various 
levels of efficacy differences. The higher costs of longer term treatment were offset 
by the increased quality of life for patients with DAS-28 < 2.6 as well as reduced 
hospitalisation costs.
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Objectives: Routine testing for HLA-B*5801 in European patients has been pro-
posed before allopurinol treatment aiming to reduce the incidence of Stevens-
Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Having some discretion 
in the allocation of financial resources, Portuguese NHS hospitals may be particu-
larly interested in this issue as extra costs with the treatment of SJS/TEN episodes 
may be avoided. This study aims to evaluate the cost-effectiveness of HLA-B*5801 
genotyping versus no genotyping (usual care) in Portuguese adult patients newly 
diagnosed with gout before allopurinol treatment. MethOds: A decision tree model 
was constructed to structure the sequences of clinical events that may occur after 
the diagnosis of the disease, over a period of three months. Effectiveness data were 
estimated for Portuguese patients based on published literature and Portuguese 
population databases. All costs were obtained from official prices published for 
the Portuguese NHS. Admitting that NHS hospitals objective is to lower costs in the 
treatment of gout, the incremental cost per SJS/TEN reaction avoided was the incre-
mental cost-effectiveness ratio (ICER) considered. One way sensitivity analysis was 
performed for each relevant parameter. Results: The use of HLA-B*5801 genotyp-
ing versus no genotyping was associated with a decrease of 1.24 SJS/TEN reactions 
and an incremental total cost of 42, 401.03€ , resulting in an ICER of 34, 194.38€ per 
SJS/TEN reaction avoided. Sensitivity analysis results showed that base-case results 
are very sensitive to variations in the baseline odds ratio of gene-disease associa-
tion, epidemiological data used to estimate the incidence of SJS/TEN and genotyp-
ing cost. cOnclusiOns: Widespread use of HLA-B*5801 genotyping in Portuguese 
hospitals is not cost-effective at the current unit price of 45.30€ as it leads to a 
substantial increase in expenditure compared to usual care. However, it may be an 
advantageous option if its maximum price would equal 6,37€ .
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Objectives: The purpose of present study was to evaluate the cost-effectiveness of 
tocilizumab (TCZ) vs. infliximab (IFX) for the treatment of patients with rheumatoid 
arthritis (RA) from the perspective of Ministry of Health (MoH) over a patient lifetime 
horizon in Kazakhstan. MethOds: A decision analytic model was constructed in 
MS-Excel to estimate effects and directs costs of methotrexate (MTX) combination 
with TCZ or IFX in hypothetical cohorts of RA patients. Treatment efficacy and 
transition probabilities were synthesized through a meta-analysis of data from 
relevant clinical trials and literature. The characteristics of patient cohort and treat-
ment costs (drug, monitoring, RA-related hospitalisation, adverse effects manage-
ment) in year 2014 Kazakhstani tenge (KZT) were estimated from republican official 
sources. Primary efﬁcacy outcome was deﬁned as an improvement of 70% in ACR 
response (ACR70), which can be regarded as a close measure of remission. Annual 
3% discounting rate and 6-month cycles were utilized for the model. Robustness of 
the model parameters was explored by one-way and probabilistic sensitivity analy-
sis. Results: For an average 70-kg patient, discounted direct costs per year were 
estimated at 4 456 000 KZT for TCZ+MTX and 3 190 000 KZT for IFX+MTX. Adjusted 
ACR70 rates were higher in TCZ+MTX group (23%) than in IFX+MTX group (17%). As 
a result of a lifetime stimulation (average 12 years) of the model, TCZ incurred 1.89 
times higher costs, and 1.67 times more achievements of ACR70 than IFX. The ICER 
was estimated to be 3 218 900 KZT per achieved ACR70, which is within the cost-
effectiveness threshold values recommended by WHO. Overall, model was sensitive 
to the changes in drug costs and patient weight. cOnclusiOns: TCZ+MTX incurred 
significantly higher costs compared to IFX+MTX, although ICER per achieved ACR70 
lays within the recommendations of WHO. Further research is necessary for other 
ACR rates. These findings may better inform decision makers regarding formulary 
inclusion and reimbursement in the treatment of RA patients in Kazakhstan.
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